SCHEMBL4668546

SCHEMBL4668546

COc1cc2nccc(Oc3ccc(NC(=O)Nc4nc(C)cs4)c(Cl)c3)c2cc1OC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.69
PDGFRA P16234 15/20 0.69
FLT1 P17948 4/20 0.69
FLT4 P35916 4/20 0.69
KIT P10721 4/20 0.69
RIPK2 O43353 3/20 0.69
STK10 O94804 3/20 0.69
ABL1 P00519 3/20 0.69
RET P07949 3/20 0.69
PDGFRB P09619 3/20 0.69
DDR1 Q08345 3/20 0.69
PTK6 Q13882 3/20 0.69
DDR2 Q16832 3/20 0.69
AURKB Q96GD4 3/20 0.69
MET P08581 3/20 0.69
EPHB2 P29323 2/20 0.69
BCR P11274 2/20 0.69
FGFR1 P11362 2/20 0.69
SLC6A3 Q01959 2/20 0.69
MAP4K2 Q12851 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4669693 0.90 KDR (0.73) KDRPDGFRAFLT1FLT4KIT
SCHEMBL4668929 0.90 KDR (0.64) KDRPDGFRAFLT1FLT4KIT
Hydrochloric Acid SCHEMBL4668966 0.90 KDR (0.71) KDRPDGFRAFLT1FLT4KIT
SCHEMBL4669708 0.87 KDR (0.60) KDRPDGFRAFLT1FLT4KIT
SCHEMBL4669698 0.87 KDR (0.68) KDRPDGFRAFLT1FLT4KIT
SCHEMBL4668970 0.87 KDR (0.67) KDRPDGFRAFLT1FLT4KIT
SCHEMBL4669686 0.85 KDR (0.69) KDRPDGFRAFLT1FLT4KIT
SCHEMBL5649290 0.84 KDR (0.77) KDRPDGFRAFLT1FLT4KIT
SCHEMBL5205475 0.84 KDR (0.74) KDRPDGFRAFLT1FLT4KIT
SCHEMBL5207916 0.84 KDR (0.78) KDRPDGFRAFLT1FLT4KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1652847-B1 Quinoline and quinazoline derivatives for the treatment of tumors KIRIN PHARMA KK (JP) 2008-05-28 EP claimed
EP-1652847-A1 Quinoline and quinazoline derivatives for the treatment of tumors KIRIN BEER KABUSHIKI KAISHA (JP) 2006-05-03 EP claimed
EP-1652847-B1 Quinoline and quinazoline derivatives for the treatment of tumors KIRIN PHARMA KK (JP) 2008-05-28 EP disclosed
US-7211587-B2 Quinoline derivatives and quinazoline derivatives having azolyl group KIRIN BEER KABUSHIKI KAISHA (KR) 2007-05-01 US disclosed
US-6821987-B2 4-SUBSTITUTED BY AZOLYLUREIDO-PHENOXY, OR PHENYLTHIO; ANTITUMOR AGENTS; TREATING DIABETIC RETINOPATHY, CHRONIC RHEUMATISM, PSORIASIS, ATHEROSCLEROSIS, KIRIN BEER KABUSHIKI KAISHA (JP) 2004-11-23 US disclosed
US-20040229876-A1 Quinoline derivatives and quinazoline derivatives having azolyl group KIRIN BEER KABUSHIKI KAISHA (JP) 2004-11-18 US disclosed
EP-1382604-A1 QUINOLINE DERIVATIVE HAVING AZOLYL GROUP AND QUINAZOLINE DERIVATIVE KIRIN BEER KABUSHIKI KAISHA (JP) 2004-01-21 EP disclosed
US-20030087907-A1 Quinoline derivatives and quinazoline derivatives having azolyl group KIRIN BEER KABUSHIKI KAISHA (JP) 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229876-A1 Quinoline derivatives and quinazoline derivatives having azolyl group NQO2, H1-5, NRAS KDR 3455/4885PDGFRA 4104/4885FLT1 2511/4885
US-20030087907-A1 Quinoline derivatives and quinazoline derivatives having azolyl group NQO2, H1-5, NRAS KDR 3455/4885PDGFRA 4104/4885FLT1 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.